Long-term prognostic significance of homocysteine in middle-aged and elderly

References

• Ahluwalia N, Blacher J, Szabo de EF, et al. (2013). Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis 228:478–84.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Bowman L, Clarke RJ, et al. (2010). Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 303:2486–94.
   PubMed Web of Science ®Google Scholar
• Bonaa KH, Ueland PM, Schirmer H, et al. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578–88.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, et al. (1999a). Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 131:352–5.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Silbershatz H, Rosenberg IH, et al. (1999b). Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159:1077–80.
   PubMed Web of Science ®Google Scholar
• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049–57.
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, et al. (1991). Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149–55.
   PubMed Web of Science ®Google Scholar
• Clarke R, Halsey J, Lewington S, et al. (2010). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170:1622–31.
   PubMed Web of Science ®Google Scholar
• den HM. (2003). Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med 41:1404–7.
   PubMed Web of Science ®Google Scholar
• den HM, Koster T, Blom HJ, et al. (1996). Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–62.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Stumpflen A, Hirschl M, et al. (1998). Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80:566–9.
   PubMed Web of Science ®Google Scholar
• Falcon CR, Cattaneo M, Panzeri D, et al. (1994). High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080–3.
   PubMedGoogle Scholar
• Fallon UB, Elwood P, Ben-Shlomo Y, et al. (2001). Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health 55:91–6.
   PubMed Web of Science ®Google Scholar
• Fermo I, Vigano' DS, Paroni R, et al. (1995). Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 123:747–53.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. (2014). Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 129:e28–292.
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Huerta JM, Fernandez S, et al. (2007). Homocysteine increases the risk of mortality in elderly individuals. Br J Nutr 97:1138–43.
   PubMed Web of Science ®Google Scholar
• Hamilton-Craig I, Colquhoun D, Kostner K, et al. (2015). Lipid-modifying therapy in the elderly. Vasc Health Risk Manag 11:251–63.
   PubMedGoogle Scholar
• He Y, Li Y, Chen Y, et al. (2014). Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis 24:1158–65.
   PubMed Web of Science ®Google Scholar
• Huang T, Chen Y, Yang B, et al. (2012). Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 31:448–54.
   PubMed Web of Science ®Google Scholar
• Igland J, Vollset SE, Nygard OK, et al. (2012). Relative importance of risk factors for coronary heart disease–the Hordaland Homocysteine study. Scand Cardiovasc J 46:316–23.
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Rosand J, Kistler JP, et al. (2002). Homocysteine, MTHFR 677C–>T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 59:529–36.
   PubMed Web of Science ®Google Scholar
• Kluijtmans LA, van den Heuvel LP, Boers GH, et al. (1996). Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35–41.
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, et al. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–77.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SH. (2002). Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 112:556–65.
   PubMed Web of Science ®Google Scholar
• Marti-Carvajal AJ, Sola I, Lathyris D. (2015). Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 1:CD006612.
   PubMed Web of Science ®Google Scholar
• McCully KS. (1969). Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–28.
   PubMed Web of Science ®Google Scholar
• Perry IJ, Refsum H, Morris RW, et al. (1995). Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395–8.
   PubMed Web of Science ®Google Scholar
• Pineda J, Marin F, Marco P, et al. (2010). The prognostic value of biomarkers after a premature myocardial infarction. Int J Cardiol 143:249–54.
   PubMed Web of Science ®Google Scholar
• Ray JG. (1998). Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 158:2101–6.
   PubMed Web of Science ®Google Scholar
• Refsum H, Smith AD, Ueland PM, et al. (2004). Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50:3–32.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Anand K, Lee HS, et al. (2004). Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study. Stroke 35:2263–9.
   PubMed Web of Science ®Google Scholar
• Sajadieh A, Nielsen OW, Rasmussen V, et al. (2005). Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 26:1402–9.
   PubMed Web of Science ®Google Scholar
• Saposnik G, Ray JG, Sheridan P, et al. (2009). Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40:1365–72.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chien KL, Hsu HC, et al. (2009). Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese. 12-year prospective cohort study. Circ J 73:1423–30.
   PubMed Web of Science ®Google Scholar
• Tsai AW, Cushman M, Tsai MY, et al. (2003). Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 72:192–200.
   PubMed Web of Science ®Google Scholar
• Verhoef P, Hennekens CH, Malinow MR, et al. (1994). A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 25:1924–30.
   PubMed Web of Science ®Google Scholar
• Virtanen JK, Voutilainen S, Happonen P, et al. (2005). Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil 12:369–75.
   PubMedGoogle Scholar
• Waskiewicz A, Sygnowska E, Broda G. (2012). Homocysteine concentration and the risk of death in the adult Polish population. Kardiol Pol 70:897–902.
   PubMed Web of Science ®Google Scholar
• Zylberstein DE, Bengtsson C, Bjorkelund C, et al. (2004). Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 109:601–6.
   PubMed Web of Science ®Google Scholar